+6504738654

SEP 2 2 2006

PTO/SB/21 (09-04)

And the Description And of 1995	U.S. P	Approved for use through 07/31/2008, OMB 0651-0031 atom and Trademark Office; U.S. DEPARTMENT OF COMMERCE ection of Information unless it displays a valid OMB control number.				
Onder the Paperwork Resident Act of Table	Application Number	10/044,692				
TRANSMITTAL	Filing Date	January 11, 2002				
FORM	First Named Inventor	Thomas R. Cech, et al.				
	Art Unit	1642				
(to be used for all correspondence effer initial		Susan NMN Ungar, Ph.D.				
Total Number of Pages In This Submission	Attorney Docket Number	015389-002640US; 018/213C				
	ENCLOSURES (Check all	that apply)				
Fee Transmittal Form  Fee Attached  Amendment/Reply  After Final  Affidavits/declaration(s)	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence A	ddress Status Letter Other Enclosure(s) (please identify				
Extension of Time Request  Express Abandonment Request Supplemental Information Disclosure Statement (2 pages)  Con Number of CD(s) Landscape Table on CD  Certified Copy of Priority Document(s)  Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53  Replace Terminal Disclaimer  Request for Refund  CD. Number of CD(s) Landscape Table on CD  Remarks  Form PTO-1449 (1 page) with attached information (4 pages)  Last page marker (1 page)						
SIGNA	TURE OF APPLICANT, ATTO	RNEY, OR AGENT				
Firm Name	Geron Corp	poration				
Signature						
Printed name  J. Michael Schiff						
Date Sept 21/06 Reg. No. 40,253						
CERTIFICATE OF TRANSMISSION/MAILING  I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:						
Signature Tausautho	Sept 21/06 Pacific Time	Sopr 23/04 East Gost Time of				
Typed or printed name		Date				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patento, P.O. Box 1450, Alexandria, VA 22313-1450.

if you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# RECEIVED CENTRAL FAX CENTER

SEP 2 2 2006

CERTIFICATE OF FACSIM	ILE TRANSMISSION			
I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office in accordance with 37 CFR § 1.6(d) on the date indicated.				
Name	Date			

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Thomas R. Cech et al.

Filing Date: January 11, 2002

Serial No: 10/044,692

Docket:

015389-002640

US; 018/213c

Title: NUCLEIC ACID VACCINE FOR ELICITING

AN IMMUNE RESPONSE AGAINST

TELOMERASE REVERSE TRANSCRIPTASE

Art Unit: 1642

Examiner: Susan N.M.N. Ungar, Ph.D.

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Alexandria VA 22313

Dear Sir,

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure. Included is a Declaration under 37 CFR § 1.56, listing related issued patents and pending applications owned or co-owned by Geron Corporation.

The Examiner is requested to consider whether any of the subject matter claimed in the patents and patent applications listed in the accompanying Declaration under 37 CFR § 1.56, or any of the prosecution history in the pending applications listed therein, is material to patentability of any claim in the present application.

PATENT USSN 10/044,692 015389-002640US 018/213c

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, or that all relevant information has been found.

This Information Disclosure Statement is being filed after the first Office Action on the merits, but before a final Office Action or Notice of Allowance, pursuant to 37 CFR § 1.197(c)(2).

A fee under 37 CFR § 1.117(p) has already paid for Information provided under 37 CFR § 1.56 since the last Office Action, and applicants respectfully submit that no additional fee is required for consideration of the enclosed information. However, in the event that the Office requires an additional fee, the Commissioner is hereby authorized to charge it to Deposit Account 07-1139.

Respectfully submitted,

J. Michael Schiff Registration No. 40,253

GERON CORPORATION 230 Constitution Drive Menlo Park, CA 94025 Telephone: (650) 473-7715 Fax: (650) 473-8654

September 21, 2006

Form 1449 (modified)	Filing Date:	January 11, 2002	U.S.S.N.	10/044.692
Form 1449 (modified)	Inventors:	T. Cech et al.	Docket:	018/213
Information Disclosure Statement By Applicant	Title:	Nucleic Acid Vaccine for Eliciting an Immune Response Against Telomerase Reverse Transcriptase	Group: Examiner:	1634 Susan Ungar, Ph.D.

#### **U.S. Patent Documents**

Examiner Initial	Ref.	Patent No.	Issue or Pub Date	Inventors:	Assignee:	Title:		
(none)								

## Foreign Patents and Published Foreign Patent Applications

Examiner Initial	Ref.	Juris- diction	Document No.	Publication Date	Assignee:	Title:	Trans- lation
(none)							

#### **Other Documents**

Examiner Initial	Ref.	Author, Title, Date, Source
	НА	Declaration under 37 CFR § 1.56 listing other issued patents and pending applications for telomerase reverse transcriptase.

Examiner	Date Considered	

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.